Balyasny Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Balyasny Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.5M	Buy	+88,240	New	+$1.41M	﹤0.01%	1979
2025 Q4	–	Sell	-217,781	Closed	-$2.41M	–	3071
2025 Q3	$2.41M	Buy	+217,781	New	+$2.38M	﹤0.01%	1720
2025 Q2	–	Sell	-110,983	Closed	-$892K	–	2810
2025 Q1	$892K	Buy	110,983 +63,471	+134%	+$514K	﹤0.01%	2044
2024 Q4	$427K	Buy	+47,512	New	+$388K	﹤0.01%	2249
2024 Q2	–	Sell	-288,875	Closed	-$1.45M	–	2558
2024 Q1	$1.45M	Sell	288,875 -598,139	-67%	-$4.06M	﹤0.01%	1655
2023 Q4	$7.97M	Buy	887,014 +624,186	+237%	+$5.14M	0.02%	942
2023 Q3	$2.04M	Sell	262,828 -542,706	-67%	-$5.31M	﹤0.01%	1370
2023 Q2	$7.8M	Sell	805,534 -506,813	-39%	-$5.26M	0.02%	887
2023 Q1	$14.4M	Buy	1,312,347 +852,516	+185%	+$7.51M	0.04%	633
2022 Q4	$1.99M	Sell	459,831 -393,956	-46%	-$2.29M	0.01%	1433
2022 Q3	$6.42M	Buy	853,787 +354,536	+71%	+$3.07M	0.02%	886
2022 Q2	$5.02M	Sell	499,251 -43,351	-8%	-$485K	0.02%	932
2022 Q1	$6.72M	Buy	+542,602	New	+$8.39M	0.02%	840
2018 Q1	–	Sell	-500,000	Closed	-$2.27M	–	1924
2017 Q4	$2.27M	Hold	500,000	–	–	0.01%	1102
2017 Q3	$3.13M	Hold	500,000	–	–	0.01%	856
2017 Q2	$3.06M	Buy	500,000 +200,000	+67%	+$1.35M	0.01%	859
2017 Q1	$2.2M	Buy	+300,000	New	+$1.39M	0.01%	891

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balyasny Asset Management's AUPH Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Aurinia Pharmaceuticals (AUPH) in Q2 2026: 88,240 shares worth $1.5M. The stake represents ﹤0.01% of the portfolio and ranks #1979 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in AUPH as recently as Q3 2025.

Balyasny Asset Management first reported a position in AUPH in Q1 2017 and has held it in 17 quarters since. The position peaked at $14.4M in Q1 2023. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Balyasny Asset Management held 88,240 shares of Aurinia Pharmaceuticals worth $1.5M as of Q2 2026.
Aurinia Pharmaceuticals was a new Balyasny Asset Management position in Q2 2026.
Aurinia Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1979 holding.
Balyasny Asset Management first reported a position in Aurinia Pharmaceuticals in Q1 2017 and has held it in 17 quarters since.
Balyasny Asset Management's Aurinia Pharmaceuticals position peaked at $14.4M in Q1 2023.
283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.